

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 8-K

Current Report  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2021

**PHARMACYTE BIOTECH, INC.**

(Exact Name of Registrant as Specified in its Charter)

Nevada  
(State or other jurisdiction of incorporation)

333-68008  
(Commission File Number)

62-1772151  
(I.R.S. Employer Identification No.)

**23046 Avenida de la Carlota, Suite 600**  
**Laguna Hills, CA**  
(Address of Principal Executive Offices)

**92653**  
(Zip Code)

Registrant's telephone number, including area code: **(917) 595-2850**

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

On June 14, 2021, PharmaCyte Biotech, Inc. ("PharmaCyte") issued a press release announcing certain details for its upcoming Annual Meeting of Stockholders. The Annual Meeting of Stockholders will be held virtually on Wednesday, June 16, 2021, at 11:00 A.M. PDT at <https://www.virtualshareholdermeeting.com/PMCB2021>. A copy of the press release is attached as Exhibit 99.1 herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 [Press Release: PharmaCyte Biotech Announces Details to Attend This Week's Virtual Annual Meeting of Shareholders.](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 14, 2021

**PHARMACYTE BIOTECH, INC.**

By: /s/ Kenneth L. Waggoner

Kenneth L. Waggoner

Chief Executive Officer, President and General Counsel

June 14, 2021



## PharmaCytE Biotech Announces Details to Attend This Week's Virtual Annual Meeting of Shareholders

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- PharmaCytE Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box<sup>®</sup>, announced today that this week's Annual Meeting of Shareholders will be held virtually on Wednesday, June 16, 2021, at 11:00 A.M., Pacific Daylight Time at

<https://www.virtualshareholdermeeting.com/PMCB2021>

By now all PharmaCytE shareholders should have received a Proxy Statement with 4 separate proposals requiring shareholders to vote on each. If a shareholder has not received a Proxy Statement, please email Investor Relations at [investorrelations@PharmaCytE.com](mailto:investorrelations@PharmaCytE.com) and a Proxy Statement will be sent to you. Shareholders can vote electronically using the information in the Proxy Statement or by calling (201) 463-8535.

PharmaCytE's Chief Executive Officer (CEO), Kenneth L. Waggoner, said of the importance of this vote prior to Wednesday's Annual Meeting, "Each shareholder voting 'yes' on the proposals, especially Proposal No. 2, is critical for PharmaCytE to remain a viable company and for its pancreatic cancer treatment to remain in development and avoid being shelved. We encourage every shareholder to obtain and read the Proxy Statement and then participate in the vote."

During the virtual meeting, the CEO will update shareholders on the latest work being done by PharmaCytE's assembled scientific team to address the FDA's requests related to the clinical hold on PharmaCytE's treatment for locally advanced inoperable pancreatic cancer. Additionally, other company business will be addressed, including a discussion on the proposals set forth in the Proxy Statement and subsequent voting.

To learn more about PharmaCytE's pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the Company's documentary video complete with medical animations at: <https://www.PharmaCytE.com/Cancer>

### About PharmaCytE Biotech

PharmaCytE Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box<sup>®</sup>." This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCytE's therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient's tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a "bio-artificial liver" and activate the chemotherapy drug at the site of the cancer. This "targeted chemotherapy" has proven effective and safe to use in past clinical trials and we believe results in little to no treatment related side effects.

PharmaCytE's therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human liver cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCytE is also considering the use of genetically modified stem cells to treat diabetes. The encapsulation of the cell lines will be done using the Cell-in-a-Box<sup>®</sup> technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a "bio-artificial pancreas" for purposes of insulin production.

### Safe Harbor

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCytE. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance, and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners to supplement our capabilities and resources, our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

More information about PharmaCytE Biotech can be found at [www.PharmaCytE.com](http://www.PharmaCytE.com). Information may also be obtained by contacting PharmaCytE's Investor Relations Department.

View source version on businesswire.com:  
<https://www.businesswire.com/news/home/20210614005212/en/>

### Dr. Gerald W. Crabtree

#### Investor Relations:

PharmaCytE Biotech, Inc.

Investor Relations Department

Telephone: 917.595.2856

Email: [InvestorRelations@PharmaCytE.com](mailto:InvestorRelations@PharmaCytE.com)

Source: PharmaCytE Biotech, Inc.

